NanoEntek, Inc. (039860.KQ)
KOSDAQ · KRW · Technology · Scientific & Technical Instruments
₩4,785 (-0.21%) as of
Key statistics
- Market cap
- 181.08B
- Dividend yield
- 0.00%
- 52-week range
- 3,015.00 – 9,390.00
- Beta
- 0.68
- Revenue (TTM)
- 44.19B
- Profit margin
- 13.26%
- Volume
- 649.01k
About NanoEntek, Inc.
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a residual white blood cell counters; ADAMII/fluorescence stem cell counter; fluorescence cell counters and cell analyzers; brightfield cell counters; somatic cell counters; live-cell imaging system; and disposable hemocytometers. The company also provides digital healthcare services integrating artificial intelligence and big data technologies. The company was founded in 1987 and is headquartered in Seoul, South Korea.
- Sector
- Technology
- Industry
- Scientific & Technical Instruments
- Headquarters
- Seoul, South Korea
- Employees
- 141
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.